Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

QuatRx Pharmaceuticals

QuatRx Pharmaceuticals?uq=UG6efJS6
2000 FOUNDED
M&A STATUS
51-60 EMPLOYEES
M&A LATEST DEAL TYPE
Description

Developer of compounds in the areas of endocrine, metabolic and cardiovascular therapeutics. The company's products are used for the treatment for vaginal atrophy, a common problem associated with estrogen deficiency in post-menopausal women as well as for the treatment of testosterone deficiency and other conditions in men.

Website
Formerly Known As
Pegasus Pharmaceuticals
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Acquirer
Shionogi Pharma
Primary Office
  • 777 East Eisenhower Parkway
  • Suite 100
  • Ann Arbor, MI 48108
  • United States
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore QuatRx Pharmaceuticals’s full profile, request a free trial.

QuatRx Pharmaceuticals Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
16. Merger/Acquisition 10-Mar-2017 00000 Completed Generating Revenue
15. Later Stage VC 00.000 00000 Completed Generating Revenue
14. Secondary Transaction - Stock Distribution 27-Nov-2013 0000 00000 Completed Generating Revenue
13. Convertible Debt 24-Apr-2009 0000 00000 Completed Generating Revenue
12. Debt - General 22-Dec-2008 00.00 00000 Completed Generating Revenue
11. Debt - General 21-Nov-2008 00.000 00000 Completed Generating Revenue
10. Later Stage VC (Series E) 22-May-2007 0000 00000 Completed Generating Revenue
9. IPO 07-Jul-2006 0000 00000 Cancelled Generating Revenue
8. Senior Debt 31-Mar-2006 $6M $78.9M Completed Startup
7. Later Stage VC (Series D) 18-Oct-2005 $20.6M $72.9M 000.00 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

QuatRx Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series D1 0,000,000 00.000000 00 00.0 00.0 00 00.0 0.00
Series D 00,000,000 00.000000 00 00.0 00.0 00 00.0 00.000
Series C 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series B 4,200,000 $0.010000 9% $1.5 $1.5 1x $1.5 6.66%
Series A 1,575,000 $0.010000 9% $1 $1 1x $1 2.5%
To view this company’s complete Cap Table, request access »

QuatRx Pharmaceuticals Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 0000000 16-May-2005 000000000000000000 Pharmaceuticals
To view this company’s complete investment and acquisition history, request access »

QuatRx Pharmaceuticals Former Investors (16)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Aboa Venture Management Venture Capital Minority 000 0000 000000 0
BankInvest Group Venture Capital Minority 000 0000 000000 0
BioFund Ventures Venture Capital Minority 000 0000 000000 0
Frazier Healthcare Partners Venture Capital Minority 000 0000 000000 0
H&B Capital Advisors Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 16 investors. Get the full list »

QuatRx Pharmaceuticals Executive Team (9)

Name Title Board
Seat
Contact
Info
Robert Zerbe MD Chief Executive Officer, Co-Founder & President
Christopher Nicholas Chief Operating Officer & Co-Founder
Stuart Dombey MD Co-Founder & Chief Scientific & Regulatory Officer
Alexander Bridges Director, Preclinical Sciences
Mary Phelps Senior Director, Clinical Development

3 Former Executives

You’re viewing 5 of 9 executives. Get the full list »

QuatRx Pharmaceuticals Board Members (5)

Name Representing Role Since Contact
Info
Nicholas Simon Self Board Member 000 0000

4 Former Board Members

You’re viewing 1 of 5 board members. Get the full list »